Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna adalimumab coverage & prior auth | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0655

    Adalimumab (Humira and biosimilars)

    Customize your policy alerts

    Sign up for Aetna Policy 0655 alerts

    Get alerted when Policy 0655 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy describing medical necessity, prescriber requirements, indications, and continuation criteria for adalimumab and listed biosimilars for Aetna members.

    Policy Summary
    PayerAetna
    PolicyAdalimumab (Humira and biosimilars)
    Policy CodePolicy 0655
    Change TypePeriodic review — no material changes
    Effective DateMar 25, 2003
    Last ReviewFeb 20, 2024
    Next Review DateOct 24, 2024
    Key ActionObtain prior authorization with documentation of indication-specific criteria and a negative TB test within 6 months for biologic‑naive patients.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MultipleFDA-approved indications
    >=10Biosimilars listed
    6 monthsTB screen required
    ListedTDM tests investigational
    J0135HCPCS referenced

    Coverage Criteria and Indications

    Initial Approval (by indication)

    Covered when the member meets indication-specific requirements listed below and has documented negative TB testing within 6 months (for biologic- or targeted-synthetic‑naive persons).

    General requirements

    • Indications list: Member has one of the listed diagnoses for which adalimumab is considered medically necessary
    Prescriber specialties: Prescriber is one of the following or prescribing in consultation with them: rheumatologist, dermatologist, gastroenterologist, ophthalmologist, oncologist or hematologist (as applicable to indication)

    Rheumatoid arthritis - Initial

    Covered when ONE of the following is met:

    Policy Summary
    PayerAetna
    PolicyAdalimumab (Humira and biosimilars)
    Policy CodePolicy 0655
    Change TypePeriodic review — no material changes
    Effective DateMar 25, 2003
    Last ReviewFeb 20, 2024
    Next Review DateOct 24, 2024
    Key ActionObtain prior authorization with documentation of indication-specific criteria and a negative TB test within 6 months for biologic‑naive patients.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsBilling and CodingPrior Authorization, Documentation, and Prescriber RequirementsBackground and DefinitionsPolicy History and References
    RA initial:
    1) Adult member who previously received a biologic or targeted synthetic indicated for moderately to severely active rheumatoid arthritis; OR 2) Adult member with moderately to severely active RA who meets ALL of: (a) either a positive test for rheumatoid factor (RF) OR anti-cyclic citrullinated peptide (anti-CCP), OR testing positive for RF and anti-CCP with elevated CRP and/or ESR; AND (b) either inadequate response to at least a 3‑month trial of methotrexate titrated to ≥15 mg/week, OR intolerance/contraindication to methotrexate (see Appendix A)

    Articular juvenile idiopathic arthritis - Initial

    Covered when ONE of the following is met for members ≥2 years:

    JIA initial: 1) Member ≥2 years who previously received a biologic or targeted synthetic indicated for moderately to severely active articular JIA; OR 2) Member ≥2 years with moderate to severely active articular JIA who has had inadequate response to methotrexate or another conventional synthetic DMARD at adequate dose/duration; OR 3) Member ≥2 years with inadequate response to scheduled NSAIDs and/or intra‑articular glucocorticoids plus one risk factor for poor outcome (e.g., involvement of ankle/wrist/hip/SI/TMJ, erosive disease, delay in diagnosis, elevated inflammatory markers, symmetric disease) AND has risk factors for severe/refractory course and at least one of: high‑risk joint involvement, high disease activity, or judged high risk for disabling joint diseaseAge ≥2 years; weight‑based dosing per labeling (see dosing section)

    Weight-based pediatric dosing guidance: 15 kg to <30 kg = 20 mg e.o.w.; ≥30 kg = 40 mg e.o.w.; see pediatric JIA labeling

    Psoriatic arthritis - Initial

    Covered when ONE of the following is met for adults:

    PsA initial: 1) Adult member who previously received a biologic or targeted synthetic indicated for active psoriatic arthritis; OR 2) Adult member with active PsA who meets either: (a) mild‑to‑moderate disease with inadequate response to methotrexate, leflunomide, or another conventional synthetic DMARD administered at adequate dose/duration, or intolerance/contraindication to those agents, or presence of enthesitis/predominantly axial disease; OR (b) severe disease

    Ankylosing spondylitis / non-radiographic axial spondyloarthritis - Initial

    Covered when ONE of the following is met for adults:

    AS/nr-axSpA initial: 1) Adult member who previously received a biologic or targeted synthetic indicated for active ankylosing spondylitis or non‑radiographic axial spondyloarthritis; OR 2) Adult member with active AS or nr‑axSpA who has had inadequate response to at least two NSAIDs given consecutively, OR intolerance/contraindication to two or more NSAIDsIn trials BASDAI ≥4 used as activity threshold

    Guideline‑consistent requirement for trial of ≥2 NSAIDs prior to TNF inhibitor

    Inflammatory bowel disease - Initial

    Covered when meeting age and disease activity thresholds:

    Crohn's disease (CD) initial: Moderately to severely active Crohn's disease in members ≥6 years of age with indication and dosing per label (induction then maintenance); prior therapy requirements referenced elsewhere (see step therapy/documentation sections)
    Ulcerative colitis (UC) initial: Moderately to severely active ulcerative colitis in members ≥5 years of age with induction dosing (160 mg Day 1, 80 mg Day 15) and maintenance dosing per label (40 mg e.o.w. starting Day 29); continuation contingent on evidence of clinical remission by 8 weeks

    Plaque psoriasis - Initial

    Covered when ONE of the following is met for adults:

    Plaque psoriasis initial: 1) Adult member who previously received a biologic or targeted synthetic indicated for moderate‑to‑severe plaque psoriasis; OR 2) Adult member with moderate‑to‑severe plaque psoriasis who has either crucial body areas affected (hands, feet, face, scalp, genitals, intertriginous sites), OR ≥10% BSA involved, OR ≥3% BSA with inadequate response or intolerance to phototherapy or systemic pharmacologic therapy (e.g., methotrexate, cyclosporine, acitretin) or clinical reason to avoid those agents

    Hidradenitis suppurativa - Initial

    Covered when ONE of the following is met for members ≥12 years:

    HS initial: 1) Member ≥12 years who previously received a biologic indicated for moderate‑to‑severe hidradenitis suppurativa; OR 2) Member ≥12 years with moderate‑to‑severe HS who has had inadequate response to an oral antibiotic regimen used for HS for at least 90 days (e.g., clindamycin, metronidazole, moxifloxacin, rifampin, tetracyclines) OR intolerance/contraindication to oral antibiotics

    Uveitis - Initial

    Covered when ONE of the following is met for members ≥2 years:

    Uveitis initial: 1) Member ≥2 years who previously received a biologic indicated for non‑infectious intermediate, posterior, or panuveitis; OR 2) Member ≥2 years with non‑infectious intermediate, posterior, or panuveitis who has had inadequate response to corticosteroids or immunosuppressive therapy (e.g., azathioprine, cyclosporine, methotrexate, mycophenolate) OR intolerance/contraindication to those agents

    Behçet’s disease and Pyoderma gangrenosum - Initial

    Covered when ONE of the following is met:

    Behcet's initial: 1) Member who previously received apremilast or a biologic indicated for Behçet's disease; OR 2) Member with Behçet's disease who has had inadequate response to at least one non‑biologic medication (e.g., azathioprine, colchicine, cyclosporine, systemic corticosteroids)
    Pyoderma gangrenosum initial: 1) Member who previously received a biologic indicated for pyoderma gangrenosum; OR 2) Member with pyoderma gangrenosum who has had inadequate response to corticosteroids or immunosuppressive therapy (e.g., cyclosporine, mycophenolate) OR intolerance/contraindication

    Immune checkpoint inhibitor-related toxicity - Initial

    Covered when MEMBER meets either of the following:

    ICI-toxicity initial: Member has severe immune checkpoint inhibitor‑related inflammatory arthritis and has had an inadequate response to corticosteroids or a conventional synthetic drug (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine) OR has intolerance/contraindication to corticosteroids and a conventional synthetic drug

    Continuation of Therapy

    Continuation is covered when the member achieves or maintains a positive clinical response as defined per indication:

    RA continuation: Achievement or maintenance of ≥20% improvement from baseline in tender joint count, swollen joint count, pain, or disability
    JIA continuation: For members ≥2 years: low disease activity or improvement in number of active joints, number of joints with limitation, or functional ability
    PsA continuation: Low disease activity or improvement in swollen/tender joints, dactylitis, enthesitis, axial disease, or skin/nail involvement
    AS/nr-axSpA continuation: Low disease activity or improvement in functional status, total spinal pain, or inflammation (e.g., morning stiffness)
    CD continuation: Remission OR improvement in abdominal pain, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance on imaging/endoscopy, or CDAI score
    UC continuation: Remission OR improvement in stool frequency, rectal bleeding, urgency, CRP, fecal calprotectin, mucosal appearance on imaging/endoscopy, or disease activity scoring tool (e.g., UCEIS, Mayo); note: continue only if clinical remission by 8 weeks for UC induction
    PsO continuation: Reduction in BSA or improvement in signs/symptoms (itching, redness, scaling) compared with baseline
    HS continuation: Reduction in abscess/inflammatory nodule count, fewer sinus tracts, decreased lesion frequency, reduced pain/suppuration, improved QoL or disease severity score
    Uveitis continuation: Reduced flare frequency, stability/improvement in AC cell grade, VH grade, visual acuity, reduction in glucocorticoid requirements, and no new active retinal/chorioretinal lesions
    ICI-toxicity continuation: Achievement or maintenance of low disease activity or improvement in signs and symptoms of immunotherapy‑related inflammatory arthritis

    Labeled Indication Coverage

    Coverage follows labeled dosing and indications; biosimilars carry largely the same labeled indications with specific pediatric/indication exceptions noted.

    Labeled Indication Coverage: Coverage follows the FDA‑approved dosing regimens and labeled indications for adalimumab and listed biosimilars; follow weight‑ and age‑based dosing in pediatric indications and note biosimilar labeling exceptions (some biosimilars omit pediatric HS, pediatric UC, or uveitis)

    See Dosing and Administration section for indication‑specific regimens

    Experimental/Investigational Indications

    Not covered / experimental and investigational uses

    Experimental/Investigational Uses: Concomitant use of adalimumab with any other biologic or targeted synthetic drug for the same indication is considered experimental/investigational; adalimumab is considered experimental/investigational for other listed conditions (including but not limited to alopecia areata, asthma, CRMO, CAPS, cystoid macular degeneration, giant‑cell arteritis, granuloma annulare, MPS I/II, lichen planus, osteoarthritis, Takayasu's arteritis, and others enumerated in policy)

    See full Experimental and Investigational list in policy chunk 34

    TDM and Antibody Testing

    Therapeutic drug monitoring

    TDM/antibody testing—experimental: Specific commercial assays (Anser ADA, InformTx TDM, ADALX) for serum adalimumab levels and anti‑adalimumab antibodies are considered experimental/investigational by Aetna because effectiveness for guiding management has not been established

    Tests considered experimental per policy

    TDM—clinical use considerations: When testing is considered as part of evaluation for primary nonresponse or secondary loss of response, testing should be accompanied by objective evidence of inflammation (endoscopy or CRP/FC) and clinical documentation; no universal numeric cut‑offs are established across assays

    Assay variability and absence of standardized cut‑offs limit interpretation

    FDA-Approved Indications (covered when selection criteria met)

    Covered when diagnosis and selection criteria per labeling/CPB are met

    FDA indications: Use for FDA‑approved indications (RA, JIA, PsA, AS, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, non‑infectious uveitis) in the age groups specified by labeling is covered when selection criteria are met

    Ankylosing Spondylitis / axial spondyloarthritis (AS / axSpA)

    Covered for active AS/axSpA in patients with inadequate response to NSAIDs (and DMARDs for peripheral disease) consistent with guideline‑based criteria

    AS coverage conditions: Active ankylosing spondylitis or axial spondyloarthritis with inadequate response to NSAIDs; recommended dosing typically 40 mg subcutaneously every other week; trial evidence (ATLAS, ABILITY‑1) demonstrated improvements including ASAS/BASDAI/ASDAS responses and MRI inflammation reductionBASDAI ≥4 used in nr‑axSpA trials

    Guideline‑consistent step from NSAIDs to TNF inhibitor for refractory axial disease

    Covered Indications with Evidence Support

    Covered when evidence and guidelines support use in the following clinical scenarios (examples drawn from cited literature):

    nr-axSpA/axial SpA: Active axial spondyloarthritis (AS or nr‑axSpA) with significant symptom burden (e.g., BASDAI ≥4) AND inadequate response/intolerance/contraindication to at least two NSAIDs; randomized trials (e.g., ABILITY‑1) showed ASAS40 and other improvements with adalimumabBASDAI ≥4; inadequate response to NSAIDs
    Peripheral spondyloarthritis: Active peripheral SpA with inadequate response to NSAIDs/DMARDs; adalimumab demonstrated improvements in global assessments, swollen joint count, BASDAI and ASDAS in RCTs
    Crohn's disease—induction/maintenance: Moderate to severe Crohn's disease where patient responds to induction dosing; continuous maintenance (40 mg e.o.w. or weekly) associated with higher remission and fewer flares/surgeries versus induction‑only/reinitiation
    Extraintestinal manifestations and uveitis: Adalimumab can be considered for certain extraintestinal manifestations of IBD (arthritis, PG, uveitis) and refractory autoimmune uveitis with supportive pilot/clinical data; individualization and specialist documentation required

    Hidradenitis Suppurativa — Initial Coverage

    Covered when consistent with evidence from HS trials

    HS coverage‑aligned criteria: Moderate to severe hidradenitis suppurativa with documentation of prior inadequate response or intolerance to conventional therapies consistent with trial populations (e.g., failure of antibiotics) AND dosing consistent with trial/label (induction then weekly or e.o.w. maintenance as labeled)

    Giant Cell Arteritis — Limited/No Benefit

    Not covered / not supported for routine use when RCTs show no benefit

    Giant Cell Arteritis: Addition of adalimumab to prednisone did not increase remission on reduced prednisone at 6 months versus placebo in an RCT; not supported for routine use in newly diagnosed GCA based on available evidence

    Uveitis-related CME — Investigational

    Insufficient evidence / investigational for ocular CME and related indications

    Cystoid macular edema (uveitic) / intra‑ocular use: Evidence limited to small non‑randomized pilot studies and case series with mixed results; intravitreal adalimumab showed no efficacy in a small series and systemic use had variable responses—considered investigational pending larger trials

    Granuloma Annulare — Salvage Use Only

    Insufficient high‑quality evidence; salvage therapy in refractory cases

    Granuloma annulare (GA) and related conditions: Evidence limited to case reports and small observational series suggesting clinical responses to TNF‑α inhibitors; adalimumab may be considered as salvage therapy for recalcitrant generalized disease but lacks RCT evidence to support routine coverage

    MPS I/II — Investigational

    Pilot data only; investigational

    MPS I/II (Hurler/Hunter) musculoskeletal manifestations: Small pilot randomized cross‑over study with very limited completers suggested possible improvement in ROM and parent‑reported pain but evidence insufficient to support routine use; investigational pending further trials

    Juvenile Idiopathic Arthritis (FDA‑approved)

    Covered when treatment aligns with indications supported by FDA approval and pivotal trial evidence:

    JIA (polyarticular) — FDA‑aligned coverage: Patient meets FDA‑approved population (polyarticular JIA) and age/weight criteria (FDA labeling: approval for patients ≥4 years for polyarticular JIA; weight‑based dosing per label); efficacy supported by pivotal 48‑week trial with maintained ACR Pedi responsesWeight‑based dosing: 15 kg to <30 kg = 20 mg e.o.w.; ≥30 kg = 40 mg e.o.w.

    Pediatric Crohn's Disease (FDA‑approved)

    Covered when treatment aligns with pediatric Crohn's disease evidence and label:

    Pediatric Crohn's disease — FDA‑aligned coverage: Patient is ≥6 years of age with moderate‑to‑severe Crohn's disease and prior therapies have failed; induction and maintenance dosing per trial/label with weight‑based regimens; clinical response/remission documented via PCDAI (remission PCDAI ≤10)

    Plaque Psoriasis (FDA‑approved)

    Covered when treatment aligns with adult plaque psoriasis labeling and trial evidence:

    Plaque psoriasis — FDA‑aligned coverage: Adult patients with moderate‑to‑severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate; dosing per label (initial 80 mg, then 40 mg one week later, then 40 mg e.o.w. maintenance); trial endpoints (e.g., PASI responses) support benefit

    Psoriatic Arthritis (FDA‑approved)

    Covered when treatment aligns with psoriatic arthritis labeling and trial evidence:

    Psoriatic arthritis — FDA‑aligned coverage: Patients with active psoriatic arthritis (e.g., ≥3 swollen and ≥3 tender joints) with inadequate response to NSAIDs or DMARDs; adalimumab may be used alone or with methotrexate; clinical benefit demonstrated by ACR20 at week 12 and inhibition of radiographic progression in trials

    Insufficient Evidence / Experimental

    Not routinely covered / investigational or insufficient evidence for benefit:

    Conditions with limited or negative evidence: Use for conditions such as MPS I/II, lichen planus, erosive/inflammatory hand osteoarthritis, lumbar disc herniation, and other indications is supported only by small pilot studies, case reports, or small RCTs with mixed or limited benefit; routine coverage not recommended without stronger evidence

    Psoriatic Arthritis — evidence of benefit

    Covered when supported by clinical trial evidence demonstrating improvement:

    PsA trial evidence: Adalimumab demonstrated superior clinical response versus placebo in psoriatic arthritis trials (e.g., ACR20 58% at week 12 vs 14% placebo) and reduced structural progression

    Rheumatoid Arthritis — guideline-aligned use

    Covered when consistent with guideline recommendations and trial evidence:

    RA guidance alignment: Adalimumab is FDA‑approved for moderately to severely active RA; randomized trials support benefit and guideline recommendations favour TNF inhibitor use after inadequate response to conventional DMARD monotherapy (methotrexate preferred)
    RA step therapy: Initiation generally follows trial of conventional DMARDs (methotrexate preferred) unless contraindicated

    Ulcerative Colitis — induction and response-based continuation

    Covered when ALL of the following are met:

    UC approval and population: Patients have moderate‑to‑severe UC (Mayo score 6–12 with endoscopy subscore 2–3) as studied in FDA trials
    UC induction dosing: FDA‑approved induction dosing: 160 mg initial, 80 mg at week 2; maintenance 40 mg every other week starting Day 29
    UC response evaluation: Continue only if evidence of clinical remission by 8 weeks; for loss of response, document objective inflammation (endoscopy or CRP/FC), exclude infection, and consider serum drug and antibody testing to guide managementRemission by 8 weeks

    Pyoderma Gangrenosum and other dermatologic/IBD-associated indications — limited evidence

    Covered in refractory or selected cases when supported by specialist documentation (case series and observational evidence):

    Pyoderma gangrenosum and related dermatologic/IBD indications: Adalimumab may be considered in refractory PG and certain dermatologic/IBD‑associated manifestations when supported by specialist documentation and case‑series/observational evidence

    Uveitis — approved indication

    Covered when diagnosis matches FDA approval:

    Uveitis approved indication: Adalimumab is FDA‑approved for non‑infectious intermediate, posterior and panuveitis in adults and pediatric patients ≥2 years; coverage when diagnosis and selection criteria align with labeling and ophthalmology guidance

    Use of serum drug and anti-drug antibody testing to evaluate loss of response

    Testing may be considered when patients have inadequate primary response or secondary loss of response and objective evidence of inflammation.

    Prerequisites for testing: All of the following: clinical evaluation for active disease; confirmation of objective inflammation (endoscopy or CRP or fecal calprotectin); exclusion of enteric infections
    Potential actionable testing results: Either: (a) low/undetectable drug level suggesting underexposure; or (b) therapeutic drug level with presence of neutralizing anti‑drug antibodies suggesting immunogenicity; or (c) therapeutic drug level without antibodies suggesting pharmacodynamic failure; note that no universal numeric cut‑offs are established

    Assay variability limits interpretation

    TDM coverage and decision criteria

    Coverage considerations for TDM and dose adjustment strategies

    Reactive TDM (adults): Reactive TDM in patients with active disease is supported as standard of care and is more cost‑effective than empiric dose escalation; reactive use is recommended by guidelines when managing loss of response
    Proactive TDM evidence is mixed: pediatric RCT (Assa et al.) showed benefit targeting ~5 µg/mL in pediatric CD, while adult RCTs (SERENE CD and others) did not demonstrate superiority of proactive TDM over clinical adjustment; proactive TDM may be considered selectively in pediatrics or specific contexts
    Use of TDM results to alter therapy: When altering dosing or switching therapy based on TDM, documentation should include trough concentration, anti‑drug antibody status, clinical disease activity measures, and CRP/endoscopic findings where available; recognize assay variability and lack of standardized thresholds

    All indications for adalimumab or listed biosimilars that are not specifically described in this policy are considered experimental and investigational and are not covered. This includes uses outside the labeled or evidence-supported indications unless otherwise documented and justified by specialty consultation and supportive clinical evidence.

    Biosimilar adalimumab products carry largely the same labeled indications as Humira, but specific biosimilars may omit certain pediatric or indication-specific approvals. For example, several biosimilars (e.g., Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, Yusimry) explicitly note they do not include pediatric indications for hidradenitis suppurativa or ulcerative colitis, or omit uveitis on their labeling. Coverage for a biosimilar must follow that product's approved labeling.

    The policy lists examples of ICD-10 diagnosis codes that are not covered for indications in this clinical policy bulletin, including active infectious and parasitic diseases (A00–B99), certain mucopolysaccharidosis codes (E76.01–E76.03; E76.1), cystoid macular degeneration (H35.351–H35.359), lichen planus (L43.0–L43.9), alopecia areata (L63.0–L63.9), granuloma annulare (L92.0), reactive arthritis (M02.30–M02.39), cryopyrin-associated periodic syndromes (M04.2), giant cell arteritis (M31.5–M31.6), and osteoarthritis ranges (M15.0–M19.93). Use for these listed ICD-10 codes may be excluded or considered investigational per the CPB.

    UpToDate reviews cited in the policy do not list adalimumab as a therapeutic option for certain conditions — for example, the UpToDate review on cryopyrin-associated periodic syndromes (CAPS) does not mention adalimumab — indicating absence of authoritative guidance supporting its use in those contexts.

    UpToDate and trial evidence summarized in the policy do not support routine use of adalimumab for age-related macular degeneration or for enabling more rapid corticosteroid tapering in newly diagnosed giant cell arteritis. The Seror et al randomized trial in GCA found no significant steroid-sparing benefit at 6 months when adalimumab was added to prednisone.

    UpToDate reviews for lichen planus (including vulvar lichen planus) do not mention adalimumab as a management option. The policy therefore characterizes use of adalimumab for lichen planus as having insufficient authoritative support and considers it investigational or salvage in nature.

    Pediatric safety and efficacy are not established for every indication. The policy notes that pediatric effectiveness data are lacking for some conditions (for example, pediatric psoriatic arthritis per product labeling) and that other pediatric uses (reactive arthritis and rare disorders) are supported only by small observational reports or case studies, limiting routine coverage in children without robust supporting evidence.

    Routine stand-alone measurement of serum adalimumab concentrations or anti-drug antibodies without corresponding clinical context and objective evidence of inflammation is not supported. The policy emphasizes that drug/antibody testing should be interpreted in conjunction with clinical disease activity and objective markers (e.g., endoscopy, CRP, fecal calprotectin) before using results to guide therapy changes.

    No universal assay cut-off values have been validated for adalimumab drug concentrations or anti-drug antibody titers. Studies show variability between assays and inconsistent thresholds relating levels to clinical remission, and the policy states that consensus cut-offs correlating with specific clinical outcomes are not established.

    The appendices and administrative/reference sections included in the policy do not list additional explicit coverage exclusions beyond those stated in the main policy sections. Reference and appendix material provide supporting detail but do not by themselves define further exclusions.

    Certain sections of the document consist of administrative or reference materials (eg, policy history, appendices, reference lists) and do not themselves specify clinical coverage criteria or exclusions. These materials are informational and do not replace the clinical criteria described in the policy body.

    Concomitant use of adalimumab with another biologic or targeted synthetic agent for the same indication is considered experimental and investigational and is not an established or covered therapeutic approach according to the policy.

    Treatment of alopecia areata with TNF inhibitors is generally not supported; clinical reports and summaries indicate lack of efficacy and instances where TNF inhibitors have induced or worsened alopecia areata. Therefore adalimumab for alopecia areata is not routinely supported by this policy.

    Use of adalimumab for chronic recurrent multifocal osteomyelitis (CRMO/CNO/SAPHO) is supported only by case reports and uncontrolled studies. The policy indicates that well-designed controlled trial evidence is lacking and routine coverage for CRMO is investigational absent strong supporting documentation.

    A randomized trial in giant cell arteritis did not show that adding adalimumab to prednisone increased the proportion of patients in remission on reduced prednisone at 6 months; the policy therefore does not support adalimumab for corticosteroid tapering in newly diagnosed GCA based on that trial.

    A randomized, placebo-controlled trial in hand osteoarthritis found no superiority of adalimumab over placebo for pain reduction in patients with analgesic- and NSAID-refractory disease, supporting the policy's classification of this indication as not supported for routine coverage.

    Widespread use of adalimumab drug level or anti-drug antibody testing for all treated patients is not supported because reliable numeric cut-offs that consistently correlate with clinical outcomes have not been established across methodologies; assay differences limit generalizability of single thresholds.

    Proactive therapeutic drug monitoring (scheduled measurement and dose adjustment to reach target troughs) is not consistently supported by randomized adult RCT evidence. Adult trials (eg, SERENE CD and prior studies) did not show additional benefit of proactive TDM over clinically guided dose adjustment, though a pediatric RCT showed benefit in a specific pediatric Crohn's population.

    The policy excerpts do not include explicit standalone statements labeled 'not medically necessary' in every section; however, several uses and tests (eg, concomitant biologics for the same indication, specific TDM assays such as Anser ADA/InformTx/ADALX) are described as experimental/investigational and therefore not considered medically necessary per the policy.

    Some document sections contain administrative text (policy history, review dates, references) and do not include clinical criteria. These administrative excerpts provide context (eg, last review 02/20/2024, effective date 03/25/2003) but do not define coverage rules.

    Billing and Coding

    Related CPT/HCPCS and related lab/imaging codesmixed
    J0135Injection, adalimumab, 20 mg
    Q5131Injection, adalimumab-aacf (idacio)
    80145Adalimumab
    71045-71048Radiologic examination, chest
    85651Sedimentation rate, erythrocyte; non-automated
    85652Sedimentation rate, erythrocyte; automated
    86140C-reactive protein
    86141C-reactive protein; high sensitivity (hsCRP)
    86200Cyclic citrullinated peptide (CCP), antibody
    86430Rheumatoid factor; qualitative
    1–10 of 16
    1/2
    HCPCS codes covered if selection criteria are metHCPCSCovered
    J0135Injection, adalimumab, 20 mg
    Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
    Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
    Other HCPCS/CPT/related codes referencedmixed
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
    J1745Injection, infliximab, 10 mg
    S9359Home infusion therapy, anti-tumor necrosis factor intravenous therapy; per diem
    ICD-10 codes covered if selection criteria are metICD-10Covered
    D89.9Disorder involving the immune mechanism, unspecified [Immune checkpoint inhibitor-related toxicity]
    H20.00 - H20.9Unspecified iridocyclitis [uveitis] [age 2 and older]
    H44.111 - H44.119Panuveitis [age 2 and older]
    H44.131 - H44.139Sympathetic uveitis [age 2 and older]
    K50.00 - K50.919Crohn's disease [regional enteritis] [active Crohn's disease with listed manifestations] [age 18 and older]
    K51.00 - K51.919Ulcerative colitis [age 5 and older]
    L40.0 - L40.9Psoriasis [age 18 and older]
    L73.2Hidradenitis suppurativa [age 12 and older]
    L88Pyoderma gangrenosum
    M05.00 - M06.39Rheumatoid arthritis [moderately to severely active in adults] [age 18 and older]
    1–10 of 13
    1/2
    ICD-10 codes not covered for indications listed in the CPBICD-10Not Covered
    A00.0 - B99.9Infectious and parasitic diseases [active]
    E76.01 - E76.03Mucopolysaccharidosis, type I
    E76.1Mucopolysaccharidosis, type II [Hunter's syndrome]
    L40.4Guttate psoriasis
    L43.0 - L43.9Lichen planus
    L63.0 - L63.9Alopecia areata
    L92.0Granuloma annulare
    M02.30 - M02.39Reiter's disease
    M04.2Cryopyrin-associated periodic syndromes (CAPS)
    M31.5 - M31.6Giant cell arteritis
    Coding notes from sectionmixed
    NDC/Humira formulations not specified in this sectionNo explicit NDCs or CPT/HCPCS codes listed in these chunks
    Pediatric weight thresholds for dosing — multiple weight cutoffs
    Pediatric Crohn's weight bands (6+ years)17 kg to <40 kg: induction 80 mg (day 1), 40 mg (day 15), maintenance 20 mg every other week; ≥40 kg: induction 160 mg (day 1, or split), 80 mg (day 15), maintenance 40 mg every other week
    Pediatric UC weight bands (5+ years)20 kg to <40 kg: induction Day1 80 mg, Day8 40 mg, maintenance starting Day29 = 40 mg every other week or 20 mg every week; ≥40 kg: induction Day1 160 mg (single or split), Day8 80 mg, maintenance Day29 = 80 mg every other week or 40 mg every week
    Adolescent HS dosing (≥12 years, ≥30 kg)30 kg to <60 kg: Day1 80 mg, Day8 and subsequent 40 mg every other week; ≥60 kg: Day1 160 mg (single or split), Day15 80 mg, maintenance Day29 onward 40 mg every week or 80 mg every other week
    Tuberculin skin test induration threshold
    TST induration threshold>= 5 mm induration considered positive per product labeling (considered positive even if prior BCG vaccination)
    TB testing methodsAcceptable tests: tuberculin skin test (TST) or interferon-gamma release assays (IGRAs); positive tests require further evaluation (e.g., chest radiograph)
    Latent TB managementTreatment of latent TB should be initiated prior to starting adalimumab per labeling
    BASDAI for AS trial inclusion
    BASDAI threshold used in nr-axSpA trialBASDAI ≥ 4 (used as inclusion criterion in the nr-axSpA trial)
    Trial contextSieper et al. evaluated patients meeting ASAS criteria with BASDAI ≥4 and significant back pain
    AS recommended dosingRecommended dosage for AS in labeling: 40 mg subcutaneously every other week
    Pediatric weight thresholds for dosing (JIA/Crohn's)
    JIA weight-based dosingFor children 15 kg to <30 kg: 20 mg every other week; ≥30 kg: 40 mg every other week (FDA‑approved for polyarticular JIA age ≥4)
    Pediatric Crohn's induction by weightFor CD: 17 kg to <40 kg induction includes 80 mg Day 1 and 40 mg Day 15 with maintenance 20 mg eow; ≥40 kg induction 160 mg Day1 and 80 mg Day15 with maintenance 40 mg eow
    Adolescent HS thresholdAdolescents ≥12 years and ≥30 kg: HS dosing per HS table (see adolescent HS weight bands)
    Adalimumab serum concentration thresholds
    Universal serum threshold statusNo validated universal adalimumab serum concentration threshold reliably associated with remission has been identified in reviewed studies
    Assay variabilityAnti-drug antibody and drug level measurements vary between commercial assays; no standardized cut-offs established
    Interpretation cautionLow‑titer antibodies may be transient/non-neutralizing; high‑titer antibodies with undetectable drug levels are more likely neutralizing and linked to loss of efficacy
    Suggested trough concentration thresholds
    Suggested troughs from cohorts/studiesAdalimumab suggested cut-offs reported: ~7.2–7.3 µg/mL (Chaparro/Barclay cohorts) associated with mucosal healing/remission in some analyses
    Infliximab suggested rangeInfliximab suggested cut-offs reported in studies: ~3.4–5.1 µg/mL for predicting mucosal healing/remission
    Pediatric RCT targetPediatric proactive TDM RCT targeted adalimumab trough of 5 µg/mL and used that target for dose adjustments

    Prior Authorization, Documentation, and Prescriber Requirements

    Prior Authorization

    Obtain prior authorization showing indication‑specific medical necessity

    Prior authorization is required and must document that the member meets the indication‑specific criteria in the policy (e.g., prior biologic/targeted‑synthetic use OR specified step and biomarker/response criteria) and that the prescriber is an appropriate specialist. For biologic‑ or targeted‑synthetic‑naive persons, document a negative TB test (PPD or IGRA) within 6 months prior to initiating therapy.

    • Medication must be prescribed by or in consultation with one of the listed specialties (see prescriber specialties).
    • Examples of indication‑specific evidence: inadequate response to methotrexate for RA, inadequate response to ≥2 NSAIDs for axial SpA, or trial of antibiotics for HS as specified in the policy.
    Billing Rule

    Use the policy‑specified HCPCS/CPT codes when submitting PA and claims

    Bill injectable adalimumab to the HCPCS/CPT codes identified by the payer. Common codes referenced include J0135 (injection, adalimumab, 20 mg) and product‑specific Q‑codes for biosimilars (e.g., Q5131). Include supporting lab/procedure codes when relevant (e.g., TB testing, CRP, imaging).

    • J0135 is listed for adalimumab 20 mg.
    • Q‑codes (e.g., Q5131 for adalimumab‑aacf/idacio) are noted for biosimilars; verify payer‑specific coding/coverage before billing.
    Prior Authorization

    Request PA for specific adalimumab product and cite applicable labeling

    Prior authorization is required for adalimumab products (J0135 and biosimilar Q‑codes) when the member meets the policy selection criteria; ensure the request identifies the exact product/formulation and aligns with the labeled indication or biosimilar labeling exceptions.

    • When requesting coverage for a biosimilar, note any indication omissions in the biosimilar labeling (e.g., some biosimilars omit pediatric HS or UC).
    • Include product name or HCPCS/Q‑code on the PA request to match payer billing requirements.
    Prior Authorization

    Provide HS diagnosis and prior‑therapy documentation for PA

    For hidradenitis suppurativa, prior authorization should include the diagnosis and documentation of prior inadequate response or intolerance to conventional therapies consistent with the PIONEER trial populations (e.g., failure of an oral antibiotic regimen for at least 90 days).

    • Document moderate‑to‑severe HS diagnosis, prior antibiotic use and duration (≥90 days), and prior biologic exposure if applicable.
    • If prior biologic was used, include agent and reason for discontinuation.
    Note
    Prior Authorization

    Submit PA evidence aligning indication with FDA labeling or pivotal trials

    Confirm the requested indication matches FDA‑approved or strong trial evidence (examples: polyarticular JIA age ≥4 with weight‑based dosing; pediatric Crohn's disease age ≥6 with trial induction/maintenance dosing). Include prior treatment history, weight for pediatric dosing, and relevant disease activity scores to support the PA.

    • For JIA, include weight and ACR Pedi responses or trial evidence alignment.
    • For pediatric Crohn's, document induction dosing used and PCDAI or clinical response per trial definitions.
    Prior Authorization

    Align PA with labeled indications and supporting evidence

    Prior authorization decisions should reflect FDA approvals and guideline recommendations for indications such as RA, UC, and non‑infectious uveitis; include indication‑specific trial evidence and the labeled dosing regimen in the PA submission.

    • For UC, include induction regimen (160 mg then 80 mg) and plan for maintenance dosing (40 mg e.o.w.) and note that continuation requires evidence of clinical remission by 8 weeks.
    • For RA, document prior DMARD use or positive biomarkers per policy criteria.
    Documentation Required

    Include clinical justification and assay details for drug/antibody testing

    Requests to perform serum adalimumab or anti‑adalimumab antibody testing must include a clinical rationale because universal cut‑offs are not established and assay variability limits interpretation; provide test methodology when available to support use of results.

    • Report the specific assay used and explain how results will affect management (e.g., dose escalation vs switch).
    • Note that low‑titer antibodies may be transient and high‑titer antibodies with undetectable drug levels are more likely to be clinically meaningful.
    Prior Authorization

    Provide clinical justification when PA seeks TDM‑based dosing changes

    When proposing dose changes or therapy decisions based on therapeutic drug monitoring (TDM), prior authorization may require supporting clinical justification because RCT evidence (e.g., SERENE CD and adult trials) does not consistently show proactive TDM improves outcomes in adults.

    • For proactive TDM‑based changes in adults, document failure of clinical‑adjustment strategies or provide rationale why TDM is preferred.
    • For pediatric cases where RCT evidence exists (e.g., select pediatric CD data), include trial alignment and target troughs if used.
    Note

    Do not rely on appendix material alone for PA requests

    No prior authorization criteria or billing code changes are specified in the appendix/reference excerpts; do not submit PA requests solely based on appendix material without citation to the main criteria sections.

    • Appendix and reference chunks contain administrative or background material only and do not establish PA criteria.
    Note

    Administrative/reference content — not PA criteria

    This portion of the document contains references and administrative material only and does not set prior authorization criteria; reference policy history (last review date) when submitting documentation if relevant.

    • Policy history: Last review 02/20/2024; Effective 03/25/2003; Next review 10/24/2024.
    Step Therapy

    Document required prior trials or intolerance for step therapy

    Prior authorization requires documentation of prior trials or intolerance/contraindication to specified conventional therapies (e.g., methotrexate, NSAIDs, antibiotics, corticosteroids, other conventional DMARDs) as applicable to the indication per policy.

    • RA: inadequate response to at least 3 months of methotrexate (titrated to ≥15 mg/week) or intolerance.
    • AS/axSpA: inadequate response to at least two NSAIDs.
    • HS: inadequate response to oral antibiotic regimen for ≥90 days.
    Prior Authorization

    Indicate biosimilar product and label exceptions on PA; follow payer substitution preferences

    Biosimilars are available and carry largely the same labeled indications as Humira, but they are not automatically interchangeable; indicate biosimilar selection and note any labeling exceptions (e.g., some biosimilars omit pediatric HS or UC) on the PA to reflect step or substitution preferences.

    • Abrilada, Amjevita, Cyltezo and others are biosimilars with some pediatric/indication omissions — include product‑specific labeling considerations in the PA.
    • Confirm payer formulary preferences for biosimilar step or substitution before initiating therapy.
    Prior Authorization

    Document NSAID failure and disease activity for AS/axSpA PA

    For ankylosing spondylitis, prior authorization should document inadequate response to NSAIDs (at least two trials) or intolerance; include BASDAI/ASDAS scores or other objective measures when available to support disease activity.

    • Trials in nr‑axSpA used BASDAI ≥4 as an inclusion criterion; include relevant disease activity indices where available.
    • Record prior NSAID agents and durations to show inadequate response.
    Step Therapy

    Document ≥2 NSAID trials before TNFi for axial SpA unless contraindicated

    Guidance sources recommend a trial of at least two NSAIDs before initiating a TNF inhibitor for active axial spondyloarthritis; document the agents and durations when requesting authorization for adalimumab.

    • If NSAID trial was not feasible, document intolerance or contraindication to support authorization.
    • Include dates and outcomes of NSAID trials in the request.
    Prior Authorization

    If adalimumab used for HS, explain why infliximab is not chosen and document prior therapies

    Clinical guidance notes infliximab as a commonly preferred agent for severe/refractory HS; when requesting adalimumab, provide rationale if infliximab is not selected or is not feasible and document prior therapies and HS severity consistent with trial populations.

    • If infliximab was not used due to IV access, contraindication, or patient factors, state this in the PA.
    • Include PIONEER trial severity measures and prior treatment history supporting adalimumab use.
    Prior Authorization

    Document prior NSAID/DMARD therapy and concomitant use rationale for PsA PA

    For psoriatic arthritis, document prior use or failure of NSAIDs and/or conventional DMARDs (e.g., methotrexate) when applicable; note whether adalimumab will be used with methotrexate or as monotherapy per trial evidence.

    • Trials commonly included patients with inadequate response to NSAIDs; include joint counts and prior DMARD history.
    • If using concomitant methotrexate, document dose and rationale.
    Step Therapy

    Document DMARD trial (methotrexate) and disease activity for RA PA

    For rheumatoid arthritis, document trial and inadequate response to conventional DMARD monotherapy (methotrexate preferred) prior to requesting a TNF inhibitor, unless there is intolerance or contraindication; include disease activity measures supporting need for biologic therapy.

    • Provide methotrexate dose/duration (≥15 mg/week) or documentation of intolerance.
    • Include objective measures (tender/swollen joint counts, CRP/ESR) as available.
    Prior Authorization

    Reflect recommended biologic sequencing for ocular Behçet and JIA‑associated uveitis in PA

    Consensus guidance places adalimumab as a first‑line biologic for ocular Behçet disease and as a second‑line option for juvenile arthritis–associated uveitis after failure of antimetabolite or calcineurin inhibitor therapy; reflect this sequencing and prior therapy in PA submissions.

    • For Behçet ocular disease, document prior therapies and specialist recommendation.
    • For JIA‑associated uveitis, document failure of antimetabolites or calcineurin inhibitors before adalimumab.
    Documentation Required

    Prefer clinical‑adjustment/reactive TDM; document failures before proactive TDM requests

    Support routine clinical‑adjustment and reactive TDM approaches: document clinical signs/symptoms and biomarker results before requesting proactive TDM; reactive TDM (testing in response to loss of response) is supported as standard care in adults.

    • If requesting proactive TDM, provide a rationale and evidence that reactive or clinical‑adjustment strategies have failed.
    • Reactive TDM requests should include current disease activity measures and reasons for testing.
    Note

    Appendix excerpts do not create new step therapy rules

    No step therapy requirements are described in the appendix/reference excerpts; do not cite appendix sections as establishing step therapy obligations when submitting PA.

    • Appendix excerpts are informational and not a source of PA step mandates.
    Note

    Do not substitute references for the policy's explicit PA criteria

    References and guideline citations in the excerpt do not themselves change PA requirements; rely on the policy's explicit criteria when preparing authorization requests.

    • Cite the policy criteria and relevant trial or guideline evidence in the PA rather than external references alone.
    Documentation Required

    Obtain documented negative TB test within 6 months and follow positive‑test workup

    Document a negative TB screening test (PPD/TST or IGRA) within 6 months prior to initiating adalimumab for biologic‑ or targeted‑synthetic‑naive persons; if TB screening is positive, obtain further testing (e.g., chest x‑ray) to exclude active disease and treat latent TB before starting therapy. Ensure the prescriber specialty is one of those listed in the policy.

    • Do not administer adalimumab to members with active TB.
    • When TST is used, an induration ≥5 mm is considered positive per product labeling.
    Documentation Required

    Document indication and dosing regimen aligned to label and patient age/weight

    Document the indication and dosing consistent with labeled regimens (e.g., Crohn's induction 160 mg then 80 mg; UC induction 160 mg then 80 mg and maintenance 40 mg e.o.w.; HS dosing: induction 160 mg then 80 mg then 40 mg weekly or 80 mg e.o.w.). Include patient age and weight for pediatric dosing.

    • Pediatric weight‑based dosing must be documented (e.g., JIA: 15 kg–<30 kg = 20 mg e.o.w.; ≥30 kg = 40 mg e.o.w.).
    • For UC, continuation limited to patients with clinical remission by 8 weeks.
    Documentation Required

    Include pre‑initiation infectious disease screening and monitoring plans

    Before initiation, document TB risk assessment and testing results (TST or IGRA and chest radiograph if indicated), hepatitis B carrier status, and plan for monitoring signs of serious infection or reactivation during therapy.

    • Screen for HBV carrier status and document management plan if positive.
    • Include chest x‑ray when TB screening is positive to exclude active disease.
    Documentation Required

    Provide disease activity indices and prior therapy response documentation

    Include diagnosis‑specific activity indices and prior treatment responses in the PA documentation (examples: BASDAI/ASDAS for axial SpA; CDAI/PCDAI and induction response for Crohn's; PASI/PGA for psoriasis).

    • For axSpA, include BASDAI or ASDAS and record inadequate response to NSAIDs.
    • For Crohn's, document response to induction dosing (e.g., CDAI decrease ≥70) when seeking maintenance approval.
    Documentation Required

    Include HS trial‑consistent severity and prior‑therapy details for PA

    For hidradenitis suppurativa PA, include documentation of prior treatments tried, duration, and HS severity consistent with PIONEER trial populations (moderate‑to‑severe HS), and indicate whether weekly or e.o.w. dosing is planned per label.

    • Document prior antibiotic regimens and durations (e.g., ≥90 days) and HS‑PGA or abscess/nodule counts if available.
    • Note whether infliximab was considered and reasons for selecting adalimumab instead.
    Documentation Required

    Submit trial‑aligned clinical documentation for FDA‑supported indications

    For indications supported by pivotal RCTs (e.g., JIA, pediatric Crohn's, plaque psoriasis, PsA), include documentation of diagnosis, prior therapies tried/failed, disease severity measures used in trials (e.g., ACR Pedi, PCDAI, PASI), and patient weight for pediatric dosing.

    • Attach trial‑aligned outcome measures (ACR Pedi scores, PCDAI, PASI) to support medical necessity.
    • For pediatric cases, explicitly state weight and match dosing to label.
    Documentation Required

    Provide objective inflammatory evidence and drug/antibody data when documenting UC loss of response

    When assessing loss of response in ulcerative colitis, include objective evidence of inflammation (endoscopy or surrogates such as CRP or fecal calprotectin), exclude enteric infections, and report serum drug and anti‑drug antibody levels when available to guide management decisions.

    • Document endoscopic findings or CRP/fecal calprotectin values and stool studies to exclude infection.
    • If sending drug/antibody levels, include assay used and interpretation relative to clinical picture.
    Documentation Required

    Attach objective inflammation data and TDM results when used to justify therapy changes

    Document objective signs of inflammation (endoscopy or CRP/fecal calprotectin) and clinical evaluation when claiming inadequate response; include serum trough concentration and anti‑drug antibody results when available to support management decisions.

    • State the assay used for drug/antibody testing and explain how results will change therapy.
    • If no objective inflammation is present, provide rationale for continued therapy or alternative management.
    Documentation Required

    Submit full TDM and clinical dataset when requesting dose changes based on levels

    When using TDM results to guide dosing or switching, provide documentation of measured trough drug concentrations, anti‑drug antibody status, clinical disease activity indices, CRP, and endoscopic findings (or rationale for absence) to support the requested change.

    • Because thresholds vary by assay, report the numeric trough value, assay method, and clinical correlation.
    • Include prior dosing history and timing of trough sample relative to dosing.
    Note

    Follow the policy's documented PA submission requirements rather than appendix text

    Appendix/reference excerpts do not provide specific documentation submission requirements; rely on the policy's documentation section for PA content rather than appendix text.

    • If uncertain, reference the policy's 'Required clinical documentation' and 'Pre‑initiation infectious disease screening' sections when preparing PA.
    Note

    Reference policy history/review dates when relevant to documentation

    Include policy review dates or policy history references when relevant to the PA submission (policy last reviewed 02/20/2024); administrative/history material alone does not establish medical necessity.

    • Cite last review date if submitting new evidence or when contesting a prior denial.
    Denial Risk

    Do not start therapy with active TB; follow positive TB screening workup

    Do not administer adalimumab to patients with active tuberculosis. If TB screening is positive, obtain further testing (e.g., chest x‑ray) to exclude active disease and initiate latent TB treatment prior to starting adalimumab.

    • A positive TB screening requires chest radiograph to exclude active pulmonary TB before initiating therapy.
    • Per labeling, treat latent TB infection before starting adalimumab.
    Denial Risk

    Concurrent biologic/targeted synthetic therapy for same indication is investigational

    Concomitant use of adalimumab with another biologic or targeted synthetic therapy for the same indication is considered experimental/investigational and may be denied; do not request concurrent biologic combinations for the same condition without strong evidence.

    • Examples include combining adalimumab with abatacept, anakinra, etanercept, infliximab, tocilizumab, or tofacitinib for the same indication.
    • If combination therapy is clinically justified (e.g., complex cases), include robust supporting evidence and rationale in the PA.
    Denial Risk

    Anser ADA, InformTx TDM, and ADALX tests are considered investigational

    Claims for Anser ADA, InformTx TDM, or ADALX serum adalimumab/antibody testing in management of adalimumab therapy are considered experimental/investigational and may be denied; provide strong clinical justification and assay details if submitted for consideration.

    • Aetna considers Anser ADA, InformTx TDM, and ADALX investigational for managing adalimumab.
    • If testing is requested, include rationale for how results will change management and the assay methodology.
    Denial Risk

    Avoid non‑covered ICD‑10 codes; submit PA only for policy‑supported diagnoses

    Use of adalimumab for indications coded within infectious/parasitic disease categories (A00‑B99) or other ICD‑10 diagnoses listed as not covered may be denied; ensure the ICD‑10 code submitted matches a policy‑supported indication.

    • Examples of not‑covered codes include active infectious and parasitic diseases (A00‑B99) and selected orphan/metabolic disorder codes listed in the policy.
    • If treating an off‑label condition, include compelling evidence and rationale in the PA, recognizing denial risk.
    Denial Risk

    Expect denial risk for off‑label uses without guideline or trial support

    Prescribing adalimumab outside labeled indications or guideline‑supported uses (off‑label) carries denial risk; include guideline support or high‑quality trial evidence and comprehensive clinical documentation when requesting PA for off‑label but guideline‑supported scenarios.

    • Examples with higher denial risk include spondyloarthritis subtypes not listed in Humira labeling.
    • Provide detailed rationale and literature support for off‑label requests.
    Denial Risk

    Giant cell arteritis use may be denied—RCT showed no steroid‑sparing benefit

    For giant cell arteritis, randomized trial evidence showed no added benefit of adalimumab plus prednisone versus placebo for steroid‑sparing remission at 6 months; absence of demonstrated benefit supports potential denial for this indication.

    • Seror et al. RCT (n=70) found no significant difference in remission on reduced prednisone at 6 months between adalimumab and placebo groups.
    Denial Risk

    Hand osteoarthritis indication has high denial risk due to negative RCT

    Adalimumab was not superior to placebo for refractory hand osteoarthritis in an RCT and this negative trial supports potential denial for that indication when requested for analgesic‑refractory hand OA.

    • Chevalier et al. randomized trial showed no significant benefit of adalimumab over placebo for hand OA pain outcomes.
    Denial Risk

    Limited‑evidence indications (e.g., LP, MPS I/II) carry denial risk

    Use of adalimumab for lichen planus or mucopolysaccharidosis I/II is supported only by case reports or very small pilot studies and UpToDate does not list adalimumab as a recommended therapy; such requests may be denied as experimental or insufficient evidence.

    • Provide strong specialty documentation and rationale if seeking authorization for these limited‑evidence indications.
    Denial Risk

    UC maintenance requires documented clinical remission by 8 weeks to continue coverage

    Continuation of adalimumab for ulcerative colitis should be limited to patients who have demonstrated clinical remission by 8 weeks of therapy; lack of remission by that time may support discontinuation or denial of continued therapy.

    • For UC, document clinical remission (Mayo score ≤2 with no subscore >1) by Day 57 to support ongoing maintenance therapy.
    • If no remission, include objective evidence and rationale for continued treatment in PA.
    Denial Risk

    Trough level results alone are unlikely to justify coverage without clinical context

    A lack of validated universal trough concentration thresholds reliably associated with remission means routine adalimumab level testing alone is unlikely to justify coverage changes; include clinical context and assay details when submitting level‑based claims.

    • Studies show overlap and variability in concentrations between responders and nonresponders and no single threshold is universally accepted.
    • Provide how the result will alter management and include objective measures of inflammation.
    Denial Risk

    Report assay method and clinical correlation—assay variability raises denial risk

    Assay variability and absence of standardized cut‑offs increase the likelihood that drug/antibody test results will be considered investigational or non‑actionable; include assay method and interpretation tied to patient‑specific clinical data when submitting requests.

    • Different commercial assays have differing sensitivity; report the assay name and method used.
    • High‑titer antibodies with undetectable drug may be more actionable than low/titular transient antibodies.
    Denial Risk

    Proactive TDM in adults may be denied—document prior clinical adjustment or reactive need

    Because proactive or reactive TDM has not demonstrated consistent superiority for improving clinical remission in adults, proactive TDM‑based monitoring used solely to justify therapy changes may be denied; document prior clinical‑adjustment attempts or reactive testing needs to support authorization.

    • Cite SERENE CD and related trials showing no clear benefit of proactive TDM over clinical adjustment in adults.
    • Reactive TDM in response to loss of response is a supported strategy; document that scenario when requesting testing.
    Note

    Appendix/reference excerpts are not actionable for PA/denial triggers

    Not applicable—these appendix/reference chunks do not specify actionable authorization or denial triggers; do not use them as standalone justification for PA decisions.

    • Use main policy criteria sections for medical necessity determinations.
    Note

    Administrative/policy history content — no clinical PA criteria

    Administrative and policy history material does not create clinical action requirements; rely on the policy's explicit criteria when preparing authorizations and appeals.

    • Policy history available: Last review 02/20/2024; effective date 03/25/2003.

    Background and Definitions

    Background: Adalimumab is a recombinant human IgG1 monoclonal antibody that binds tumor necrosis factor-alpha (TNF-α) and inhibits its activity. It is FDA-approved for multiple immune-mediated inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/non-radiographic axial spondyloarthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, non-infectious uveitis, Behçet’s disease, and pyoderma gangrenosum; the policy lists age thresholds and dosing regimens for adult and pediatric indications and aligns coverage with labeled indications and supporting trial evidence.

    Positive clinical response / continuation criteria
    Indication-specific response definitionPositive clinical response/continuation defined per indication as achievement or maintenance of low disease activity or improvement in disease‑specific measures (examples: joints for RA/JIA, CDAI for Crohn's, Mayo/UCEIS for UC, PASI/BSA for psoriasis)
    Crohn's disease specificsFor CD continuation: remission OR improvement in abdominal pain, diarrhea, weight, hematocrit, mucosal appearance, or CDAI score
    Uveitis specificsFor uveitis continuation: reduced flare frequency, stability/improvement in AC cell grade, vitreous haze, visual acuity, or reduced glucocorticoid requirements
    Biosimilar (Abrilada example)
    Abrilada labeling caveatAbrilada is a biosimilar to Humira but is not interchangeable; it carries the same labeled indications as Humira except for pediatric use in hidradenitis suppurativa and ulcerative colitis
    Substitution statusAbrilada is not automatically substitutable with Humira per product labeling
    Product formAbrilada supplied as 0.8 mL prefilled pen containing 40 mg
    Unbranded generic
    Unbranded generic noteAdalimumab‑adaz (Hyrimoz) is noted as a biosimilar and adalimumab‑adaz is also available as an unbranded generic
    Hyrimoz formulation detailsHyrimoz is supplied as single‑dose prefilled pens and syringes in multiple strengths (10 mg, 20 mg, 40 mg, 80 mg presentations)
    Labeling exceptionsHyrimoz carries the same indications as Humira except for uveitis and pediatric HS/UC per labeling
    Adalimumab — mechanism
    Mechanism of actionAdalimumab is a recombinant human IgG1 monoclonal antibody that binds and inhibits tumor necrosis factor alpha (TNF‑α), blocking its inflammatory effects
    Clinical effectBlocks TNF‑α–mediated induction of pro‑inflammatory cytokines, leukocyte migration, and acute phase reactants
    Product nameAvailable as Humira (and multiple biosimilars) for subcutaneous injection
    axial spondyloarthritis (axSpA) — definition
    axSpA definition — groupAxial spondyloarthritis (axSpA) is a group of inflammatory conditions primarily affecting the spine; includes ankylosing spondylitis (radiographic) and non‑radiographic axSpA (nr‑axSpA)
    Clinical featuresTypically presents with chronic back pain before age 45 and may include peripheral joint involvement; diagnosis requires combination of features and exclusion of other causes
    Subclassification noteAS shows radiographic sacroiliitis; nr‑axSpA may show MRI evidence of SI joint inflammation without radiographic changes
    axial spondyloarthritis (axSpA) — additional definition
    axSpA clinical impactAxial spondyloarthritis is a potentially disabling inflammatory arthritis that typically affects the spine and may affect peripheral joints
    Diagnosis complexityNo single historical, physical, lab, or imaging finding is sufficient alone; diagnosis relies on combination of features and exclusion of mimics
    Age of onsetSymptoms typically begin before age 45
    Clinical remission in Crohn's disease (trial definition)
    CDAI remission definition (trial)Clinical remission in Crohn's disease in trials defined as Crohn's Disease Activity Index (CDAI) score < 150
    Trial endpointsCHARM and related trials used CDAI <150 at weeks 26 and 56 as co‑primary remission endpoints
    Maintenance superiorityContinuous maintenance dosing (weekly or every other week) associated with higher remission vs placebo in responders
    Hidradenitis Suppurativa (HS)
    HS definition and pivotal trialsHidradenitis suppurativa is a chronic inflammatory skin disease for which adalimumab is FDA‑approved for moderate to severe disease based on PIONEER I and II (two pivotal phase 3 trials)
    Trial outcomesPIONEER studies (n=633) showed greater reductions in abscess and inflammatory nodule counts with adalimumab vs placebo
    Adolescent eligibilityAdalimumab approved for adolescents ≥12 years with weight‑based dosing per label
    Cystoid Macular Edema (CME) — evidence note
    CME secondary to uveitis — characterizationCystoid macular edema is retinal swelling from intraocular inflammation; studies of systemic or intravitreal adalimumab show mixed and limited evidence
    Pilot study findingsDiaz‑Llopis pilot (n=19) reported control of inflammation in 63% and CME resolution in ~54% of affected eyes after 12 months, but relapses occurred
    Intra‑vitreal trialSmall intra‑vitreal series (n=8) showed no significant improvement in BCVA or CRT; overall evidence insufficient for routine use
    Polyarticular juvenile idiopathic arthritis (JIA)
    Polyarticular JIA — definition and age indicationPolyarticular juvenile idiopathic arthritis affects ≥5 joints, often symmetric; adalimumab FDA‑approved for patients 4 years and older
    Weight‑based dosingDosing in JIA is weight‑based: 15 kg to <30 kg = 20 mg eow; ≥30 kg = 40 mg eow
    Safety signalsAdverse reactions in children similar to adults; serious infections observed in ~4% within ~2 years in trials
    Pediatric Crohn's Disease — clinical response/remission metrics
    Pediatric Crohn's response/remission metricsClinical response defined by reduction in PCDAI; clinical remission defined as PCDAI ≤10 in Hyams et al. pediatric trial
    Maintenance dosing stratificationHyams trial used high (40 mg or 20 mg eow for ≥40 kg or <40 kg) versus low (20 mg or 10 mg eow) maintenance regimens after induction
    Induction regimens by weightInduction schedules: 160/80 mg or 80/40 mg depending on weight (per trial and label) with maintenance per weight band
    ACR20
    ACR20 definitionACR20 = American College of Rheumatology 20% improvement response used as a primary efficacy endpoint in rheumatology trials (e.g., PsA)
    Trial contextAdalimumab showed 58% ACR20 at week 12 vs 14% for placebo in PsA trials
    Use in PsACan be used with or without methotrexate per trials
    PASI 75 / PASI 90
    PASI definitionsPASI 75 and PASI 90 denote 75% and 90% improvements from baseline in Psoriasis Area and Severity Index, used to assess skin response
    Trial resultsIn PsA patients with psoriasis, 59% achieved PASI75 and 42% PASI90 at 24 weeks on adalimumab versus ~1% with placebo
    TimingPASI endpoints commonly assessed at week 16–24 in pivotal trials
    Mayo score — UC definition
    Mayo score usageMayo score is a composite clinical and endoscopic score for UC; clinical remission in FDA trials defined as Mayo ≤2 with no subscore >1 after 8 weeks
    Trial populationFDA UC trials enrolled patients with baseline Mayo 6–12 and endoscopy subscore 2–3; remission assessed at 8 weeks
    Continuation requirementContinue therapy only in patients who show evidence of clinical remission by 8 weeks per labeling
    Therapeutic drug monitoring (TDM)
    TDM definitionTherapeutic drug monitoring (TDM) = measurement of serum adalimumab concentration, often with reflex testing for anti‑drug antibodies to inform causes of nonresponse or loss of response
    Role in managementTDM is recommended when evaluating inadequate primary response or secondary loss of response alongside objective evidence of inflammation (endoscopy, CRP, FC)
    Assay/interpretation limitsAssay variability and lack of standardized cut‑offs limit broad interpretability of TDM results
    ADALX test — ELISA assay
    ADALX assay typeADALX is an ELISA‑based commercial assay (Adalimumab Quantitative with Reflex to Antibody, Serum) for adalimumab levels with reflex anti‑adalimumab antibody testing
    Assay variabilityELISA and other commercial assays show variable detection of anti‑drug antibodies and lack standardized reporting/cut‑offs
    Clinical utilityCurrent evidence insufficient to recommend routine measurement of antibodies to adalimumab as standalone management tool
    Therapeutic drug monitoring (TDM) — definition (duplicate)
    TDM concept (duplicate)Measurement of drug and anti‑drug antibody serum concentrations during maintenance or when loss of response is suspected to guide dosing or switching decisions
    Proactive vs reactive distinctionProactive TDM = scheduled monitoring to achieve target troughs before loss; Reactive TDM = testing in response to clinical loss of response
    Evidence summaryRCTs in adults show mixed/no consistent benefit of proactive TDM for clinical remission; pediatric RCT showed benefit for proactive strategy targeting 5 µg/mL
    Proactive TDM
    Proactive TDM definitionProactive TDM = scheduled trough monitoring and dose/interval adjustment to achieve target trough concentrations before loss of response
    Pediatric RCT evidenceAssa et al. pediatric RCT used proactive monitoring targeting 5 µg/mL and demonstrated higher sustained corticosteroid‑free remission vs reactive monitoring
    Adult evidence caveatAdult RCTs (e.g., SERENE CD) did not consistently show superiority of proactive TDM over clinical adjustment
    Reactive TDM
    Reactive TDM definitionReactive TDM = measurement of trough drug concentrations and anti‑drug antibodies in response to clinical loss of response to guide management
    Guideline supportSystematic reviews and guidelines favor reactive TDM as cost‑effective compared with empiric dose escalation
    Documentation neededWhen using reactive TDM to change therapy, include trough level, antibody status, clinical indices, and objective inflammation markers
    Adalimumab and biosimilars — product list summary
    Referenced product listAdalimumab and biosimilars referenced include Humira and multiple biosimilars such as Yuflyma, Yusimry, Amjevita, Cyltezo, Abrilada, Hulio, Hadlima, Idacio, Hyrimoz
    Label differences noteSome biosimilars omit specific pediatric or indication claims (examples: Abrilada and Hyrimoz omit certain pediatric HS/UC or uveitis indications)
    Substitution statusBiosimilars are not automatically interchangeable with Humira per product statements
    Clinical Policy Bulletin — Aetna CPB definition and note
    Clinical Policy Bulletin definitionAetna's Clinical Policy Bulletin provides guidance to assist in administering plan benefits and is not a member contract; it describes coverage criteria and is subject to plan terms
    Review datesPolicy last review: 02/20/2024; Effective date: 03/25/2003; Next review: 10/24/2024
    PurposeUsed to define medical necessity, prescriber requirements, indications, and continuation criteria for adalimumab and listed biosimilars

    Policy History and References

    2024-02-20policy_reviewLatest

    Policy last reviewed on 02/20/2024 (documentation of review recorded).

    2003-03-25policy_effective

    Policy effective date established as 03/25/2003.